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Background and purpose: We have shown that in vitro treatment with cannabidiol
(CBD, 2 h) enhances endothelial function in arteries from Zucker diabetic fatty (ZDF)
rats, partly due to a cyclooxygenase (COX)-mediated mechanism. The aim of the
present study was to determine whether treatment with CBD in vivo would also enhance
endothelial function.
Experimental approach: Male ZDF rats, or ZDF Lean rats, were treated for
7 days (daily i.p. injection) with either 10mg/kg CBD or vehicle (n = 6 per group).
Sections of mesenteric resistance arteries, femoral arteries and thoracic aortae
were mounted on a wire myograph, and cumulative concentration-response curves
to endothelium-dependent (acetylcholine, ACh, 1 nM–100 µM) or endothelium-
independent (sodium nitroprusside, SNP, 1 nM–100 µM) agents were constructed.
Multiplex analysis was used to measure serum metabolic and cardiovascular
biomarkers.
Key results: Vasorelaxation to ACh was significantly enhanced in mesenteric arteries
from CBD-treated ZDF rats, but not ZDF Lean rats. The enhanced vasorelaxation in ZDF
mesenteric arteries was no longer observed after COX inhibition using indomethacin or
nitric oxide (NO) inhibition using L-NAME. Increased levels of serum c-peptide, insulin
and intracellular adhesion molecule-1 observed in the ZDF compared to ZDF Lean rats
were no longer significant after 7 days CBD treatment.
Conclusion and implications: Short-term in vivo treatment with CBD improves ex
vivo endothelium-dependent vasorelaxation in mesenteric arteries from ZDF rats due to
COX- or NO-mediated mechanisms, and leads to improvements in serum biomarkers.
Keywords: cannabinoid, sodium nitroprusside, vasorelaxation, nitric oxide, cyclooxygenase, ZDF rats
Abbreviations: ACh, acetylcholine; APAI1, active plasminogen activator inhibitor-1; BNP, brain natriuretic peptide;
CBD, cannabidiol; COX, cyclooxygenase; C-Peptide, connecting peptide; EDHF, endothelium-derived hyperpolarizing
factor; ERK1/2, extracellular regulated kinase 1/2; GIP, gastrointestinal peptide; GLP-1, glucagon-like peptide-1; iCAM,
intracellular adhesion molecule-1; IL-6, interleukin-6; MCP-1, monocyte chemoattractant protein; NO, nitric oxide; PP,
pancreatic polypeptide; PYY, peptide YY; S1, schedule 1 method; SNP, sodium nitroprusside; TIMP 1, tissue inhibitor of
metalloproteinases 1; TNFα, tumor necrosis factor alpha; VEGF, vascular endothelial growth factor; vWF, von Willebrand
factor; ZDF lean rat, non-diabetic control strain for ZDF rats; ZDF rat, Zucker diabetic fatty rat.
Frontiers in Pharmacology | www.frontiersin.org 1 May 2017 | Volume 8 | Article 248
fphar-08-00248 May 18, 2017 Time: 15:14 # 2
Wheal et al. Cannabidiol Improves Vasorelaxation in Diabetes
INTRODUCTION
Cannabidiol is a non-psychoactive phytocannabinoid, which is
well tolerated in humans and already on the market as part of
a licensed treatment for spasticity in multiple sclerosis (Sativex R©
GW Pharmaceuticals, Cambridge, UK). CBD alone (Epidiolex R©,
GW Pharmaceuticals, Cambridge, UK) is in Phase 3 clinical trials
in children with intractable epilepsies (Dravet Syndrome and
Lennox-Gastaut Syndrome). Epidiolex has also received orphan
designation status in the United States for the treatment of
neonatal hypoxia-ischaemic encephalopathy. CBD is the focus
of much research because of its potential in a number of
other therapeutic areas. This is due to its anti-inflammatory,
anti-convulsant, anti-oxidant, anxiolytic, anti-nausea, anti-
tumoural and anti-psychotic properties (Mechoulam et al., 2002;
Campos et al., 2016; Fasinu et al., 2016; Leo et al., 2016;
Rohleder et al., 2016). A number of preclinical studies have also
shown beneficial effects of CBD in a range of disorders of the
cardiovascular system (Stanley et al., 2013a).
In diabetes, in vivo treatment with CBD is anti-inflammatory
and can prevent, and delay, the onset of type 1 diabetes in
non-obese diabetic prone mice (Weiss et al., 2006), and decreases
myocardial dysfunction, cardiac fibrosis and oxidative stress in
diabetic cardiomyopathy (Rajesh et al., 2010). CBD treatment
also blocks the increases in iCAM-1 and VEGF in the retina from
streptozotocin-induced diabetic rats (El-Remessy et al., 2006).
CBD has anti-nociceptive effects against diabetic peripheral
neuropathy in mice (Toth et al., 2010) and Sativex is reported
to be beneficial in patients with neuropathic pain associated
with diabetes or allodynia, although not an official indication
for the drug (Hoggart et al., 2015). Together, this suggests that
CBD may be effective against a number of diabetes related
complications.
Cannabidiol causes vasorelaxation in isolated arteries of rats
and in humans (O’Sullivan et al., 2009; Stanley et al., 2015).
We have also shown that 2h incubation in vitro with CBD
can enhance aortic and femoral artery vasorelaxation to ACh
(Stanley et al., 2013b). In femoral arteries, this mechanism
of endothelium-dependent vasorelaxant enhancement by CBD
was mediated via CB2 cannabinoid receptors, raised superoxide
dismutase activity, elevated COX activity, and activation of
vasodilatory EP4 prostanoid receptors (Wheal et al., 2014). Using
ZDF rats as a model of type 2 diabetes, the aim of the present
study was to determine if chronic in vivo treatment with CBD




Male ZDF rats (ZDF, n = 12) and the control strain ZDF
Lean rats (Lean, n = 12); Charles River, USA) were housed in
groups of 2 or 3 in the University of Nottingham Biomedical
Services Unit with a 12 h light/dark cycle, a temperature of
22 ± 2◦C, and access to Purina 5008 chow and water ad libitum.
Rats were treated for 7 days (daily i.p. injection) with either
10 mg/kg CBD or vehicle (in a volume of 1 ml/kg; n = 6
per group). This dose was chosen based on other positive
studies with CBD in diabetic models which have used 5 (Weiss
et al., 2008), 10 (El-Remessy et al., 2010; Toth et al., 2010),
or 20 (Rajesh et al., 2010; Toth et al., 2010) mg/kg. Pure
CBD was dissolved in a vehicle of 3:1:16 solution of ethanol:
Tween 80: 0.9% Saline. All procedures were in accordance with
the UK Home Office Animal (Scientific Procedures) Act 1986.
Following the treatment period, the rats (aged 12–13 weeks
old) were stunned by a percussive blow to the head, and
killed by cervical dislocation. Post-mortem blood samples were
collected, and serum extracted by centrifugation (1000 g for
10 min) and then frozen (−80◦C) for later use. Blood glucose
concentrations were measured using an Accu-Chek Aviva blood
glucose monitoring system (Roche Diagnostics Ltd., Mannheim,
Germany).
Ex Vivo Assessment of Vasorelaxation
In order to examine the potential effects of CBD on a variety of
arteries, we examined small third order arteries of the mesenteric
bed (resistance arteries), femoral arteries and the thoracic aorta.
Thoracic aortae and femoral arteries were dissected into rings
and mounted on fixed hooks, and third-order mesenteric arteries
were mounted on 40 µm diameter tungsten wires in a multi-
channel wire myograph (Models 610M and 620M, Danish Myo
Technology, Aarhus, Denmark). The arteries were bathed in
warmed (37◦C) and gassed (95% O2/5% CO2) modified Krebs’–
Henseleit solution (mM: 118 NaCl, 4.7 KCl, 1.2 MgSO4, 1.2
KH2PO4, 25 NaHCO3, 10 D-glucose, 2 CaCl2), with femoral and
mesenteric arteries set to a resting tension of 4.9 mN, and thoracic
aortic rings set to 9.81 mN. PowerLab 4/30 and 8/30 recording
systems were used to record changes in tension (ADInstruments,
Oxfordshire, UK). After an equilibration period, the arteries were
contracted twice with a high K+ ion containing buffer (mM:
62.5 NaCl, 59.4 KCl, 1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3,
10 D-glucose, 2 CaCl2) to test for vessel viability. Those
arteries which increased in tone above 4.9 mN were considered
viable.
Arteries were contracted with methoxamine (α-adrenoceptor
agonist (0.5–100 µM), and once a stable tone was reached
of approximately 80% of that achieved with high K+
buffer, cumulative concentration-response curves to the
endothelium-dependent vasorelaxant ACh (1 nM–100 µM) or
the NO donor SNP (1 nM–100 µM) were constructed.
In some vessels, the role of NO was assessed by addition
of the NO synthase inhibitor L-NAME (300 µM), and the role
of prostanoids by was investigated using the COX inhibitor
indomethacin (3 µM).
Serum Biomarkers
The levels of metabolic (Milliplex R© MAP Kit RMHMAG-84K)
and cardiovascular (Milliplex R© MAP Kit RCVD1-89K, Milliplex R©
MAP Kit RCVD2-89K) biomarkers in serum were quantified
using the Luminex R© xMAP R© technology, using commercially
available panels according to the manufacturer’s instructions.
Serum levels of ET-1 were measured using a Duoset ELISA kit
from R&D systems R©.
Frontiers in Pharmacology | www.frontiersin.org 2 May 2017 | Volume 8 | Article 248
fphar-08-00248 May 18, 2017 Time: 15:14 # 3
Wheal et al. Cannabidiol Improves Vasorelaxation in Diabetes
Data Analysis and Statistical Procedures
Sigmoidal concentration-response curves were fitted by Prism
(GraphPad Software, California, USA) to mean percentage
relaxations of methoxamine-induced tone, with error bars
representing standard error of the mean (SEM), and n being the
number of arteries from different animals. Maximal relaxation
(Rmax) and the log of the concentration of agonist that produces a
half-maximal response (EC50) were calculated from these curves.
Comparisons of concentration-response curves in CBD-treated
versus vehicle-treated arteries were performed using two-tailed
unpaired t-tests of calculated EC50 and Rmax values, and P< 0.05
taken as significant unless otherwise stated. Where sigmoidal
curves were not representative of the data, points were joined by
lines, and percentage relaxations values at specific concentrations
were compared using two-tailed unpaired t-test. Results from the
serum assays were reported as mean± SEM, and were compared
by 1-way ANOVA with post hoc analysis.
Drugs, Chemical Reagents, and Other
Materials
Acetylcholine, methoxamine, SNP, indomethacin, L-NAME
and ethanol were purchased from Sigma (Poole, UK). All
physiological salts were bought from Fischer Scientific
(Loughborough, UK). CBD was a generous gift from GW
Research Ltd (Cambridge, UK). 0.9% sodium chloride was
made by Macopharma Ltd (Twickenham, UK). TWEEN 80 was
produced by Fischer. Stock solutions of indomethacin were made
to 10 mM in ethanol, and L-NAME was made to 100 mM in
distilled water. Serial dilutions of ACh and SNP were made using
distilled water.
RESULTS
Prior to, and following, 7 days of treatment, ZDF rats were
heavier than ZDF lean rats (see Table 1). There was no difference
in the weight gain over 7 days in the ZDF Lean or diabetic rats
treated with CBD compared to vehicle (Figures 1A,B). However,
the vehicle-treated ZDF rats had a significant increase in weight
over time (P < 0.05 at day 8) that was not observed in the CBD-
treated ZDF rats (see Figure 1B). Post-mortem blood glucose
levels were not different between groups treated with vehicle
versus CBD, but were higher in ZDF rats compared to ZDF Lean
rats (P < 0.0001, Table 1).
The Effects of CBD Treatment on
Vasorelaxant Responses
Treatment with CBD did not alter vasorelaxation to ACh or
SNP in any arteries taken from ZDF Lean rats (Figures 2A,
3A, 4A). By contrast, treatment of ZDF rats with CBD
significantly enhanced the efficacy (EC50) and maximal (Rmax)
response to ACh in third order mesenteric arteries (G3)
(Figure 2B). The enhanced vasorelaxation to ACh observed
in CBD-treated ZDF mesenteric arteries was not seen in the
presence of indomethacin (Figure 2D) or the NO inhibitor
L-NAME (Figure 2F). In all vehicle-treated arteries from the ZDF
diabetic rats, a contractile response to the highest concentrations
TABLE 1 | Body weights (g) of ZDF Lean and ZDF rats recorded prior (day 1) and after (day 8) daily i.p. injection of vehicle or 10 mg/kg CBD.
ZDF vehicle-treated ZDF CBD-treated Lean vehicle-treated Lean CBD-treated
Day 1 Weight (g) 374.0 ± 27.9∗∗∗∗ 365.0 ± 25.30∗∗∗∗ 297.3 ± 19.7 288.2 ± 12.4
Day 8 / S1 Weight (g) 380.3 ± 32.0∗∗∗∗ 363.5 ± 17.00∗∗∗ 310.2 ± 20.0 300.2 ± 13.4
Day 8 post-mortem blood glucose (mM) 20.3 ± 5.8∗∗∗∗ 23.2 ± 3.3∗∗∗∗ 7.10 ± 0.77 6.70 ± 1.16
On the 8th day, rats were reweighed, killed by a Schedule 1 procedure (S1, a percussive blow to the head and cervical dislocation), and their blood glucose levels
measured (mM). Data are mean ± SD. n = 6 animals per group. Data were analyzed by repeated measures 2 way ANOVA. ∗∗∗P < 0.001 and ∗∗∗∗P < 0.0001 denotes
a significant difference between ZDF versus lean rats (vehicle-treated versus vehicle-treated, CBD-treated versus CBD-treated).
FIGURE 1 | Change in body weights (1g from Day 1 weight) of ZDF Lean (A) and ZDF rats (B) recorded daily during 7 days i.p. injection of vehicle or 10mg/kg
CBD. On the 8th day, rats were killed by a Schedule 1 procedure. Data are mean ± SD. n = 6 animals per group. Data were analyzed by one-way ANOVA and
Bonferroni post hoc test of selected pairs.
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FIGURE 2 | The effect of CBD (open symbols) or vehicle (closed symbols) treatment on ex vivo responses to ACh (A–F) and SNP (G,H) in rings of
third-order mesenteric arteries taken from ZDF Lean (left side) or ZDF rats (right side). Some arteries were incubated in vitro in the presence of 3 µM indomethacin
(squares, C,D), or 300 µM L-NAME (upward triangles, E,F). Data are mean ± SEM, n = 5/6. ∗P < 0.05 comparing the potency (EC50) and efficacy (Rmax) of Ach in
ZDF arteries after 7 days CBD treatment.
of Ach (30 and 100 µM) was observed, but this was not
seen in the arteries from ZDF rats that were treated with
CBD.
In general, Ach was less efficacious in femoral arteries than
G3 (Rmax ∼ 65 versus ∼90% relaxation), especially in the
presence of L-NAME, suggesting NO to be the main mediator of
vasorelaxation in these arteries. In femoral arteries, an enhanced
maximal (Rmax) vasorelaxant response to ACh was only observed
in CBD-treated ZDF rats in the presence of indomethacin
(Figure 3D).
In the aortae, treatment with CBD did not change vasorelaxant
responses to ACh or SNP in either strain of rat compared
to vehicle-treated controls (Figures 4A,B,G,H). However, an
enhanced vasorelaxation to ACh at 10 µM was seen in aortae
from CBD-treated ZDF rats that were pre-incubated with
L-NAME (Figure 4F). In contrast, in aortae taken from CBD-
treated ZDF Lean rats and incubated with L-NAME showed
a reduction in the maximal vasorelaxant response to ACh
(Figure 4E).
Serum Biomarkers of Metabolic and
Cardiovascular Function
Serum levels of insulin and C-peptide were greater in ZDF
rats than ZDF lean rats (P < 0.05, Figures 5A–C). Seven days
treatment with CBD reduced these to a level which was no
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FIGURE 3 | The effect of CBD (open symbols) or vehicle (closed symbols) treatment on ex vivo responses to ACh (A–F) and SNP (G,H) in rings of femoral
arteries taken from ZDF Lean (left side) or ZDF rats (right side). Some arteries were incubated in vitro in the presence of 3 µM indomethacin (squares, C,D), or
300 µM L-NAME (upward triangles, E,F). Data are mean ± SEM, n = 5/6. ∗∗P < 0.01 comparing the efficacy (Rmax) of Ach in ZDF arteries after 7 days CBD
treatment.
longer statistically different to the ZDF lean rats. Leptin followed
a similar trend, but to a level that did not reach statistical
significance (p= 0.0503).
There were no significant differences between ZDF lean and
ZDF rats, or between vehicle-treated versus CBD-treated rats
with regards to serum GLP-1, glucagon, MCP-1, PP, amylin, GIP,
IL-6, TNF-alpha or PYY (data not shown).
Zucker diabetic fatty rats had higher levels of vWF,
A-PAI1, and iCAM than their age-matched ZDF Lean controls
(Figures 6B,C,G). Treatment of ZDF rats with CBD reduced
the level of iCAM to a level that was no longer significantly
different to the ZDF lean rats (Figure 6G), but levels of
vWF and A-PAI1 were not affected. Serum VEGF and
endothelin-1 levels were significantly higher in the ZDF rats
after CBD-treatment compared to the ZDF Lean controls
(Figures 6E,H).
DISCUSSION AND CONCLUSION
The aim of this study was to establish if in vivo treatment
with CBD could improve vascular function, and we have
demonstrated that just 7 days treatment with CBD enhanced
endothelium-dependent vasorelaxation in mesenteric arteries
from ZDF rats due to COX- and NO-mediated mechanisms.
Seven days treatment with CBD was also associated with a
positive change in the profile of circulating metabolic and
cardiovascular proteins. These data support the growing evidence
that cannabinoids, and specifically CBD, maybe be a beneficial
treatment of diabetes (Sidney, 2016).
We previously showed that 2 h incubation of arteries in vitro
with CBD can enhance aortic and femoral artery vasorelaxation
to ACh (Stanley et al., 2013b; Wheal et al., 2014). We have
now extended this work to show that 7 days treatment in vivo
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FIGURE 4 | The effect of CBD (open symbols) or vehicle (closed symbols) treatment on ex vivo responses to ACh (A–F) and SNP (G,H) in aortic rings
taken from ZDF Lean (left side) or ZDF rats (right side). Some arteries were incubated in vitro in the presence of 3 µM indomethacin (squares, C,D), or 300 µM
L-NAME (upward triangles, E,F). Data are mean ± SEM, n = 5/6. ∗P < 0.05 by t-test of percentage vasorelaxation at 10 µM Ach comparing responses to Ach in ZDF
arteries after 7 days treatment with CBD, ∗∗P < 0.01 by t-test between Rmax values comparing responses to Ach in ZDF arteries after 7 days treatment with CBD.
FIGURE 5 | Circulating metabolic hormones in serum samples from ZDF Lean (circles and squares) and ZDF rats (triangles) that were treated with
either vehicle (circles and upward triangles) or 10 mg/kg CBD (i.p., 7 days; squares and downward triangles). Data are mean ± SEM, with n = 6 animals
per group. ∗P < 0.05.
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FIGURE 6 | Circulating cardiovascular biomarkers in serum samples from ZDF Lean (circles and squares) and ZDF rats (triangles) treated with either
vehicle (circles and upward triangles) or 10 mg/kg CBD (i.p., 7 days; squares and downward triangles). Data are mean ± SEM, with n = 6 animals per
group. ∗P < 0.05. ∗∗P < 0.01, ∗∗∗P < 0.001.
with CBD also improves vasorelaxation to ACh. This enhanced
vasorelaxant response after CBD treatment was inhibited in
the presence of indomethacin or L-NAME, suggesting that
this is both COX- and NO-dependent, which is in agreement
with our previous findings of COX- (Wheal et al., 2014) and
NO- (Stanley et al., 2015) dependent mechanisms of action for
CBD in the vasculature. Daily treatment with CBD did not
affect vasorelaxation to ACh in mesenteric arteries from the
ZDF lean control rats, suggesting that the positive vascular
effects of CBD are revealed when vascular dysfunction is present.
This is consistent with the known pro-homeostatic properties
of cannabinoids, where they only affect the functioning of a
perturbed system, but not a healthy one.
Zucker diabetic fatty rats used in this study were heavier,
and had higher glucose levels, than the lean control rats.
In ZDF diabetic rats, a contractile response to ACh was
observed in mesenteric arteries at concentrations above
10 µM that was not observed in the CBD-treated diabetic
animals or the ZDF lean control rats (see Figure 2B). This
contractile response was also partly reduced in the presence
of indomethacin (Figure 2D), thus it is tempting to suggest
that this contractile response in the diabetic rats (not observed
in the lean controls) is as a consequence of COX-derived
vasoconstrictor production (Feletou et al., 2011; Matsumoto
et al., 2015), and that CBD inhibits either the production,
or action, of these COX-derived vasoconstrictors in diabetic
rats.
In femoral arteries, treatment with CBD did not significantly
improve vasorelaxation to ACh or SNP, but there was a trend
for enhanced responses in both the lean and diabetic rats,
which became significant for diabetic rats in the presence of
indomethacin (Figure 3D). Similarly, although CBD treatment
did not affect vasorelaxation to ACh in diabetic aortae, a
significant effect of CBD was revealed in the presence of L-NAME
(Figure 4F). The ability of CBD to augment endothelium-
dependent vasorelaxation when either of the two of the main
vasodilatory pathways are inhibited suggests that CBD may be
enhancing vasorelaxation through another as yet unidentified
mechanism. It also highlights the benefit of CBD in maintaining
endothelium-dependent vasorelaxation in diabetic arteries when
either vasodilator prostanoids or NO become more dysfunctional
(Feletou et al., 2011; Prieto et al., 2014).
The ZDF rats used in this study had significantly raised
circulating levels of c-peptide, insulin, leptin, vWF, A-PAI1 and
iCAM, as would be expected from a model of type 2 diabetes.
Treatment with CBD for 7 days reduced the levels of c-peptide,
insulin, leptin and iCAM, such that they were no longer
significantly different to the ZDF lean controls. Although these
values were not significantly different from the vehicle-treated
ZDF diabetic rats, we predict that more prolonged treatment
with, or higher dose of, CBD might show a greater effect. Of note,
the metabolic parameters were particularly affected by CBD, but
without changes in blood glucose levels.
We recently performed a Phase II clinical trial assessing the
effects of CBD on HDL-cholesterol in type 2 diabetic patients
(Jadoon et al., 2016). A range of cardiovascular secondary
and tertiary endpoints were included, although none were
significantly affected by CBD, we suspect it was because the
dose of CBD was too low. In the present study we used
a dose of 10 mg/kg (equivalent to 800 mg per day in an
80 kg person), while in the clinical trial we used a dose
of 100 mg, twice daily. In a recent study, we showed that
a single dose of 600 mg CBD significantly reduced blood
pressure and the blood pressure response to stress in healthy
volunteers Please update (Jadoon et al., 2016). Further clinical
studies with diabetic patients are required to examine doses of
CBD more equitable to those observed in preclinical diabetes
studies.
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Of the biomarkers tested, circulating levels of VEGF and
Endothelin-1 were raised by CBD treatment in the ZDF diabetic
rats. We have previously found that CBD significantly increases
VEGF secretion from endothelial cells (Hind et al., 2016),
while El-Remessey and colleagues showed that CBD reduced
retinal expression of VEGF in streptozotocin-treated rats (El-
Remessy et al., 2006). We are not aware of any studies that have
investigated the effects of CBD on Endothelin-1, although an
increase in endothelin-1 is not consistent with an improvement
in vascular function. Thus, the vascular significance of changes in
VEGF or Endothelin-1 with CBD requires further investigation.
In conclusion, this study has shown that a short in vivo
treatment protocol with CBD was associated with improvements
in endothelium-dependent vasorelaxation in mesenteric arteries,
and an improvement in the profile of cardiovascular and
metabolic parameters. Further research is required to establish if
this effect can be maintained and/or enhanced by more prolonged
CBD treatment. The current study supports the growing evidence
that CBD may be beneficial against a number of problems
associated with diabetes including inflammation (Weiss et al.,
2006, 2008; Lehmann et al., 2016), endothelial dysfunction
(Rajesh et al., 2007), cardiomyopathy (Rajesh et al., 2010), retinal
function (El-Remessy et al., 2006, 2010), and neuropathic pain
(Toth et al., 2010).
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